[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Castle Biosciences Inc (CSTL)

Castle Biosciences Inc (CSTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 639,356
  • Shares Outstanding, K 30,330
  • Annual Sales, $ 344,230 K
  • Annual Income, $ -24,160 K
  • EBIT $ -25 M
  • EBITDA $ 12 M
  • 60-Month Beta 1.11
  • Price/Sales 1.95
  • Price/Cash Flow 19.86
  • Price/Book 1.45

Options Overview Details

View History
  • Implied Volatility 75.82% (+6.65%)
  • Historical Volatility 87.10%
  • IV Percentile 70%
  • IV Rank 55.42%
  • IV High 101.74% on 02/20/26
  • IV Low 43.60% on 08/19/25
  • Expected Move (DTE 19) 2.77 (13.15%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 2
  • Volume Avg (30-Day) 85
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 404
  • Open Int (30-Day) 505
  • Expected Range 18.31 to 23.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.38
  • Number of Estimates 1
  • High Estimate $-0.38
  • Low Estimate $-0.38
  • Prior Year $0.15
  • Growth Rate Est. (year over year) -353.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.72 +18.95%
on 05/14/26
25.70 -17.98%
on 05/04/26
-3.16 (-13.04%)
since 04/29/26
3-Month
17.72 +18.95%
on 05/14/26
29.37 -28.23%
on 03/02/26
-8.49 (-28.71%)
since 02/27/26
52-Week
14.59 +44.48%
on 08/04/25
44.28 -52.39%
on 01/26/26
+4.85 (+29.88%)
since 05/28/25

Most Recent Stories

More News
Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

FRIENDSWOOD, Texas , May 13, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its...

CSTL : 21.08 (-4.66%)
Castle Biosciences' AdvanceAD-Txâ„¢ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation

This marks the fifth MedTech Breakthrough Award that Castle has earned for its innovative testing solutions

CSTL : 21.08 (-4.66%)
Castle Biosciences Reports First Quarter 2026 Results

Delivered Q1 2026 revenue of $83.7 million Q1 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased...

CSTL : 21.08 (-4.66%)
Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month

Longstanding   collaborations with   AIM at Melanoma, the Melanoma Research Foundation,   The   Skin Cancer Foundation, IMPACT Melanoma and The   Sun Bus continue to   advance...

CSTL : 21.08 (-4.66%)
New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus

Clinical studies from Mayo Clinic researchers demonstrate the TissueCypher test provides improved risk stratification and influences risk-aligned surveillance decisions in clinical practice, with one study...

CSTL : 21.08 (-4.66%)
Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS

Multi-center clinical and population-based data show that DecisionDx-Melanoma identifies biologically high-risk patients—including those with thin and early-stage disease—and provides recurrence risk...

CSTL : 21.08 (-4.66%)
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026

FRIENDSWOOD, Texas , April 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will...

CSTL : 21.08 (-4.66%)
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year

FRIENDSWOOD, Texas , April 10, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has...

CSTL : 21.08 (-4.66%)
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026

Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Melanoma significantly stratifies five-year melanoma-specific survival within American Joint Committee...

CSTL : 21.08 (-4.66%)
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB

Among all patients studied, 2.6% nodal positivity and 97.8% three-year recurrence-free survival (RFS) was observed in those predicted to have less than 5% risk of a positive sentinel lymph node (SLN) by...

CSTL : 21.08 (-4.66%)

Business Summary

Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States.

See More

Key Turning Points

3rd Resistance Point 22.97
2nd Resistance Point 22.55
1st Resistance Point 21.82
Last Price 21.08
1st Support Level 20.67
2nd Support Level 20.25
3rd Support Level 19.52

See More

52-Week High 44.28
Fibonacci 61.8% 32.94
Fibonacci 50% 29.43
Fibonacci 38.2% 25.93
Last Price 21.08
52-Week Low 14.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.